The European Union has approved Lecanemab, a groundbreaking drug developed by Biogen to slow down the progression of Alzheimer’s disease. Manufactured in Luterbach, Switzerland, it targets harmful amyloid proteins in the brain, improving cognitive function in early-stage patients. Despite some…

The European Medicines Agency (EMA) has recommended the approval of Lecanemab, an antibody that may slow the progression of Alzheimer’s disease, specifically for patients with light cognitive impairment and minimal risk factors. This marks the first EU endorsement targeting the…